Alnylam PharmaceuticalsALNY
About: Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Employees: 2,230
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
58% more first-time investments, than exits
New positions opened: 95 | Existing positions closed: 60
32% more repeat investments, than reductions
Existing positions increased: 233 | Existing positions reduced: 176
17% more call options, than puts
Call options by funds: $195M | Put options by funds: $166M
4.4% more ownership
Funds ownership: 94.55% [Q3] → 98.94% (+4.4%) [Q4]
4% more funds holding
Funds holding: 555 [Q3] → 579 (+24) [Q4]
10% less capital invested
Capital invested by funds: $33.4B [Q3] → $30B (-$3.36B) [Q4]
43% less funds holding in top 10
Funds holding in top 10: 7 [Q3] → 4 (-3) [Q4]
Research analyst outlook
13 Wall Street Analysts provided 1 year price targets over the past 3 months
13 analyst ratings
Morgan Stanley Michael Ulz 21% 1-year accuracy 4 / 19 met price target | 11%upside $268 | Equal-Weight Maintained | 11 Apr 2025 |
Needham Joseph Stringer 22% 1-year accuracy 26 / 118 met price target | 32%upside $320 | Buy Reiterated | 9 Apr 2025 |
HC Wainwright & Co. Patrick Trucchio 15% 1-year accuracy 28 / 187 met price target | 107%upside $500 | Buy Reiterated | 2 Apr 2025 |
Scotiabank Greg Harrison 24% 1-year accuracy 10 / 41 met price target | 41%upside $342 | Sector Outperform Maintained | 31 Mar 2025 |
Redburn Atlantic Joshua Smith 0% 1-year accuracy 0 / 2 met price target | 46%upside $353 | Buy Initiated | 31 Mar 2025 |
Financial journalist opinion
Based on 9 articles about ALNY published over the past 30 days









